June 2025 highlights: strengthening our AI-driven drug discovery platform
An AI patent to advance drug discovery and diagnostics
We at Renovaro have secured a new U.S. patent for BioSymetrics’ (a Renovaro company) AI framework, advancing our mission to modernize drug discovery and diagnostics. The patent protects novel methods for harmonizing fragmented biomedical data – including genomics, imaging, and clinical records – into a unified structure for predictive modelling. This addresses a longstanding barrier in pharmaceutical R&D: translating disparate data into actionable insights.
Our patented methods are designed for distributed and parallel computing, enabling scalable, real-time analytics across a range of biomedical applications. Combined with our 2022 patent on machine learning pipeline optimization, this new IP further strengthens the foundation of our end-to-end AI platform – enhancing its value for commercial partners and supporting innovation in personalized medicine.
Victoria Catterson, Data Community Innovator for the Michael J. Fox Foundation
Victoria Catterson, VP of Data Science Research at BioSymetrics (a Renovaro company), was named a Data Community Innovator by the Michael J. Fox Foundation (MJFF) for her leadership within the Parkinson’s research community and her active contributions to the MJFF Community of Practice. She will join 12 other global researchers in sharing expertise on data analysis and engagement with the Parkinson’s Progressive Markers Initiative (PPMI) dataset. Her appointment reflects our commitment to collaborative science and underscores our dedication to advancing open, data-driven neurological research.
Renovaro is planning a webinar this July highlighting Victoria’s work with the MJFF – stay tuned for details.
Read more: https://www.renovarogroup.com/article/victoria-catterson-data-community-innovator-mjff
Renovaro at BIO 2025
At BIO 2025 in Boston, our team – including Gabe Musso, Chief Scientific Officer of BioSymetrics (a Renovaro company) – joined industry peers to showcase our Oncology and Neurology programs. Oncology remains competitive but focused, with strong interest in biomarker-driven, translational approaches. Neurology stood out as a rising priority, especially in non-opioid pain – a key focus of our KCC2 program. We were also encouraged by unexpected interest in applying neuroscience innovations to companion-animal health, highlighting potential directions for platform expansion.
Read more: https://www.renovarogroup.com/article/reflections-from-bio-2025
Join us as we drive AI-driven precision medicine forward
There’s much more ahead – join us as we push the boundaries of AI-driven precision medicine, especially in Oncology and Neurology. Follow and tag us on LinkedIn, X (formerly Twitter), Bluesky, and Threads.
